Scientists: Vaccine To Prevent AIDS May Be Within Reach

Scientists: Vaccine To Prevent AIDS May Be Within Reach
World

Since a 2009 clinical trial in Thailand showed that it was possible to prevent HIV infection in humans, new discoveries have been made that could permanently prevent AIDS. Scientists believe that a licensed vaccine is within reach to prevent AIDS.

Over 34 million people are infected with HIV worldwide, with 2.7 million new infections in 2010.

The HIV virus is one of the hardest to attack because it has many different strains. “The virus is far more crafty than we ever thought,” said Haynes, who will outline progress in vaccine research at the International AIDS Society’s 2012 conference being held in Washington from July 22-27.

With recent advances in preventative drugs, new infections have fallen by 21 percent since 1997.

Research teams have been developing vaccines for nearly three decades, but it wasn’t until RV144 — the 2009 clinical trial of over 16,000 adults in Thailand — that researchers achieved some success.

The study tested Sanofi’s ALVAC, a weakened canary pox virus used to sneak three HIV genes into the body, and AIDSVAX, a vaccine originally made by Roche Holding’s Genentech that carried an HIV surface protein.

Both vaccines did not do well in individual trials, but the final results of the study revealed that the vaccine combination cut HIV infections by 31.2 percent.

The study found that people who were vaccinated made antibodies to a specific region of the virus’s outer coat, revealing that the region may provide a vaccine target.

Preparations are being made for a follow-up trial testing more advanced versions of the vaccines among heterosexuals in South Africa and homosexual men in Thailand.

The trial will use a Sanofi vaccine, as well as a new vaccine candidate with a boosting agent from Novartis.

One researcher, Michael, said that it has been difficult securing new research partners and funding, as well as support from host countries and getting Novartis and Sanofi to work together.

“We’re really working as fast as we can,” said Michael, who expects large-scale effectiveness studies to start in 2016.

The goal is to have at least 50 percent effectiveness. Michael believes that this could be the pathway to getting the first HIV vaccine licensed by 2019.

Michael’s team is also developing a vaccine with Harvard University and Johnson & Johnson’s Crucell unit, which uses weakened versions of a common cold virus and a smallpox virus.

A study published in February showed this vaccine protected monkeys from a virulent strain of HIV. Animals that did become infected after repeated exposure also had low levels of virus in their blood. Studies in humans are beginning.

This month, NIAID will spend up to $186 million over the next seven years to fund the Centers for HIV/AIDS Vaccine Immunology & Immunogen Discovery. The consortium will focus on creating vaccines that induce protective antibodies.

Elite.

Share Tweet
React
Like Us On Facebook
Like Us On Facebook

Julian Sonny

From the sandy beaches of Hawaii, to the streets of New York: Julian has seen it all. His lifetime of travels has given him a broad scope of knowledge and an eclectic taste unlike any other in the tri-state area. Julian has often been compared to cultural icon, The Rock, because of his unequivocal work ethic and warrior-like stature.

More In World

Also On Elite

Technology

This Onesie With Built-In WiFi Is Every Hipster’s Dream (Photos)

The Internet of Things is a term commonly employed in the burgeoning world of tech. Simply put, it refers to equipping any range of objects with Internet capabilities (think manufacturing a toaster with WiFi). As always, The Internet of Things is a surprising phenomenon, forcing us to re-imagine the way we conceptualize commonplace objects by […]

Sports

2014 NBA Draft Preview: Are These Underclassmen Everything They’re Hyped Up To Be?

This year’s upcoming NBA draft class is expected to be the best since 2003, which headlined players like LeBron James, Carmelo Anthony and Dwayne Wade. Some of the anticipated freshmen in this draft have been described as having a multitude of praiseworthy adjectives. Players, such as Andrew Wiggins, have been dubbed as “the next LeBron […]